---
title: "Baxter Earnings: What To Look For From BAX"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294145212.md"
description: "Baxter International reports earnings Thursday before market open. Last quarter, the company beat revenue and EPS estimates. This quarter, analysts expect flat year-on-year revenue growth, a slowdown from last year's 4.3% increase. Baxter has missed revenue estimates multiple times recently. Peers like Abbott Labs and Intuitive Surgical reported strong results. Baxter shares are up 11.3% over the last month, trading above the average analyst price target of $22.96."
datetime: "2026-07-29T03:10:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294145212.md)
  - [en](https://longbridge.com/en/news/294145212.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294145212.md)
generator: "portal-rs"
---

# Baxter Earnings: What To Look For From BAX

Healthcare company Baxter International will be reporting results this Thursday before market open. Here’s what you need to know.

Baxter beat analysts’ revenue expectations last quarter, reporting revenues of $2.70 billion, up 2.9% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is Baxter a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Baxter’s revenue to be flat year on year, slowing from the 4.3% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Baxter has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Baxter’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Abbott Laboratories delivered year-on-year revenue growth of 13%, beating analysts’ expectations by 0.7%, and Intuitive Surgical reported revenues up 18.5%, topping estimates by 2.5%. Abbott Laboratories traded up 12.8% following the results while Intuitive Surgical was down 14.1%.

Read our full analysis of Abbott Laboratories’s results here and Intuitive Surgical’s results here.

There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 4.4% on average over the last month. Baxter is up 11.3% during the same time and is heading into earnings with an average analyst price target of $22.96 (compared to the current share price of $24.50).

**ONE MORE THING: The $21 AI Application Stock Wall Street Forgot.** While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. **Read the FREE Report Before They Notice**.

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [BAX.US](https://longbridge.com/en/quote/BAX.US.md)
- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)
- [ISUL.US](https://longbridge.com/en/quote/ISUL.US.md)

## Related News & Research

- [IFP Advisors Inc Grows Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/298421693.md)
- [Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms](https://longbridge.com/en/news/298316210.md)
- [An NEA partner says not every AI task needs frontier intelligence](https://longbridge.com/en/news/298434703.md)
- [How Meta tried, and failed, to grab its employees' data for AI](https://longbridge.com/en/news/298706095.md)
- [Anthropic's AI fluency chief says the best AI users know when to do the work themselves](https://longbridge.com/en/news/298433044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**